Olga Vasiljeva

Publications by

Browse all publications

2016

Biochimie

Learn more



In vivo imaging of protease activity by Probody therapeutic activation

Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin

Cystatin C deficiency suppresses tumor growth in a breast cancer model through decreased proliferation of tumor cells

Crumpled aluminum hydroxide nanostructures as a microenvironment dysregulation agent for cancer treatment

The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation

Stefin A-functionalized liposomes as a system for cathepsins S and L-targeted drug delivery

The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by [sup](89)Zr-immuno-PET in xenograft bearing mice

Monitoring protease activity in biological tissues using antibody prodrugs as sensing probes

2020

Multiscale biomechanics and tribology of inorganic : in memory of professor Sergey Psakhie

Learn more



Application of crumpled aluminumhydroxide nanostructures for cancertreatment

Novel ex vivo zymography approach for assessment of protease activity in tissues with activatable antibodies

2021

Multiscale biomechanics and tribology of inorganic : in memory of professor Sergey Psakhie

Learn more



Nanomaterials interaction with cell membranes : computer simulation studies

2021

Clinical cancer research

Learn more



First-in-human study of the biodistribution and pharmacokinetics of [sup](89)Zr-CX-072, a novel immunopet tracer based on an anti-PD-L1 probody

2021

Cancer immunology research

Learn more



Conditional PD-1/PD-L1 probody therapeutics induce comparable antitumor immunity but reduced systemic toxicity compared with traditional anti–PD-1/PD-L1 agents

2021

Proceedings of the National Academy of Sciences of the United States of America

Learn more



Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

2021

Metastasis : methods anad protocols

Learn more



Analyzing the role of proteases in breast cancer progression and metastasis using primary cells from transgenic oncomice

2023

International journal of molecular sciences

Learn more



The role of cysteine protease cathepsins B, H, C, and X/Z in neurodegenerative diseases and cancer

A new cathepsin D targeting drug delivery system based on Immunoliposomes functionalized with lipidated pepstatin A

2024

Mouse models of cancer : methods and protocols

Learn more



Isolating primary tumor cells from the MMTV-PyMT mouse model and their use in developing an orthotopic mouse model of breast cancer

2025

International journal of molecular sciences

Learn more



Structural and proteomic analysis of the mouse cathepsin B-DARPin 4m3 complex reveals species-specific binding determinants

Navigating the clinical landscape of liposomal therapeutics in cancer treatment

Stefin B and cystatin C deficiency suppresses tumor growth and alters tumor microenvironment in a breast cancer model

2020

Clinical cancer research

Learn more



Probody therapeutic design of 89Zr-CX-072 promotes accumulation in PD-L1-expressing tumors Compared to normal murine lymphoid tissue

Computational indicator approach for assessment of nanotoxicity of two-dimensional nanomaterials

2022

Molecular cancer therapeutics

Learn more



Nonclinical efficacy and safety of CX-2029, an anti-CD71 probody–drug conjugate

2022

Clinical cancer research

Learn more



Praluzatamab ravtansine, a CD166-Targeting antibody–drug conjugate, in patients with advanced solid tumors: an open-label phase I/II trial

Olga Vasiljeva

olga.vasiljeva@ijs.si

Publications by

Olga Vasiljeva

In vivo imaging of protease activity by Probody therapeutic activation

Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin

Cystatin C deficiency suppresses tumor growth in a breast cancer model through decreased proliferation of tumor cells

Crumpled aluminum hydroxide nanostructures as a microenvironment dysregulation agent for cancer treatment

The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation

Stefin A-functionalized liposomes as a system for cathepsins S and L-targeted drug delivery

The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by [sup](89)Zr-immuno-PET in xenograft bearing mice

Monitoring protease activity in biological tissues using antibody prodrugs as sensing probes

Application of crumpled aluminumhydroxide nanostructures for cancertreatment

Novel ex vivo zymography approach for assessment of protease activity in tissues with activatable antibodies

Nanomaterials interaction with cell membranes : computer simulation studies

First-in-human study of the biodistribution and pharmacokinetics of [sup](89)Zr-CX-072, a novel immunopet tracer based on an anti-PD-L1 probody

Conditional PD-1/PD-L1 probody therapeutics induce comparable antitumor immunity but reduced systemic toxicity compared with traditional anti–PD-1/PD-L1 agents

Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

Analyzing the role of proteases in breast cancer progression and metastasis using primary cells from transgenic oncomice

The role of cysteine protease cathepsins B, H, C, and X/Z in neurodegenerative diseases and cancer

A new cathepsin D targeting drug delivery system based on Immunoliposomes functionalized with lipidated pepstatin A

Isolating primary tumor cells from the MMTV-PyMT mouse model and their use in developing an orthotopic mouse model of breast cancer

Structural and proteomic analysis of the mouse cathepsin B-DARPin 4m3 complex reveals species-specific binding determinants

Navigating the clinical landscape of liposomal therapeutics in cancer treatment

Stefin B and cystatin C deficiency suppresses tumor growth and alters tumor microenvironment in a breast cancer model

Probody therapeutic design of 89Zr-CX-072 promotes accumulation in PD-L1-expressing tumors Compared to normal murine lymphoid tissue

Computational indicator approach for assessment of nanotoxicity of two-dimensional nanomaterials

Nonclinical efficacy and safety of CX-2029, an anti-CD71 probody–drug conjugate

Praluzatamab ravtansine, a CD166-Targeting antibody–drug conjugate, in patients with advanced solid tumors: an open-label phase I/II trial

Theranostic applications of an ultra-sensitive T1 and T2 magnetic resonance contrast agent based on Cobalt ferrite spinel nanoparticles